IRVINE, Calif.--(BUSINESS WIRE)--Cerebain Biotech Corp. (“Cerebain” or “the Company”), a subsidiary of Discount Dental Materials, Inc. (OTC Markets: DDOOD), announced today that its patent application was published electronically by the USPTO. The Company’s patent revolves around the discovery of products for the treatment of Alzheimer’s disease utilizing Omentum. Cerebain’s President, Gerald DeCiccio, stated: “The purpose of the publication is to inform the public of the existence of the application and to provide the owner of the application with certain rights. These rights permit us, under certain circumstances, to claim compensation from others who use our claimed patent without authorization. We are excited about this important step as part of the patent approval process.”
